Botanix Pharmaceuticals' (ASX:BOT) axillary hyperhidrosis product, Sofdra, has exceeded the competing product Qbrexza in the week ending February 27, according to a Tuesday note by Euroz Hartleys.
Euroz Hartleys said that an estimated 2,726 prescriptions of Sofdra were dispensed in the period, according to Symphony Health, which shows 15% week-on-week growth and the highest weekly prescription level on record.
Given its role as corporate adviser, the research firm said it is restricted from providing a price target or rating at this time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.